Product Datasheet

Cyr61/CCN1 Antibody [DyLight 550] NB100-356R

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-356R

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-356R



NB100-356R

Cyr61/CCN1 Antibody [DyLight 550]

Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Polyclonal
Preservative	0.05% Sodium Azide
Isotype	IgG
Conjugate	DyLight 550
Purity	Immunogen affinity purified
Buffer	50mM Sodium Borate
Product Description	
Host	Rabbit
Gene ID	3491
Gene Symbol	CCN1
Species	Human, Mouse, Rabbit
Reactivity Notes	Rabbit reactivity reported in scientific literature (PMID: 22401280). Mouse reactivity reported in scientific literature (PMID: 27776183).
Immunogen	A synthetic peptide made to the human CYR61 protein sequence (between residues 150-250). [UniProt# 000622]
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Product Application Details	
Applications	Western Blot, Simple Western, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Block/Neutralize
Recommended Dilutions	Western Blot, Simple Western, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Block/Neutralize
Application Notes	Optimal dilution of this antibody should be experimentally determined.

www.novusbio.com



Images

Immunocytochemistry/Immunofluorescence: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ICC/IF staining of 3 tissue arrays with 104 invasive ductal carcinoma tissue sections with metastatic carcinomas, 21 invasive ductal carcinoma tissue sections, & 8 normal tissue sections. 33 carcinoma tissue sections were -ve for estrogen & progesterone receptor; don't overexpress Her2neu receptor (triple negative breast cancer, TNBC). (A) Cyr61/CCN1 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue & lymph node sections of 104 patients (B); representative ICC/IF stains analyzed with 100x oil objective. (C) From 123 invasive ductal carcinomas tissue sections, 33 stated as being TNBC. (D) Normal breast tissue sections (n = 8) analyzed for Cyr61/CCN1 and/ or S100A4 expression using ICC/IF. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication

(https://www.frontiersin.org/article/10.3389/fonc.2019.01074/full), licensed under a CC-BY license.

Western Blot: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] -ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) & CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive CYR61 breast cancer cell lines treated with 10 µM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. n = 3; *P < 0.05;**P < 0.01;***P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection & compared to spheroid area at time point 0 (adding of Matrigel + 10 µM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; **P < 0.01;***P < 0.005;****P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown & AlamarBlue reduction was assessed 48 h after adding Matrigel & 10 µM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; *P < 0.05;**P < 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31709177), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Publications

Hellinger JW, HUchel S, Goetz L et al. Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion Front Oncol. 2019-10-23 [PMID: 31709177] (Human)

Details:

Citation used the Alexa Fluor 488 format of this antibody.





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NB100-356R

DCYR10	Cyr61/CCN1 [HRP]
210-TA-005	TNF-alpha [Unconjugated]
NBP2-34944-5ug	Recombinant Human Cyr61/CCN1 Protein
NBP2-24891R	Rabbit IgG Isotype Control [DyLight 550]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-356R

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

